Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IVVD Stock Forecast 2026-2027
$1.03
Current Price
$303.45M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to IVVD Price Targets
+870.9%
To High Target of $10.00
+870.9%
To Median Target of $10.00
+870.9%
To Low Target of $10.00
IVVD Price Momentum
-9.6%
1 Week Change
-29.5%
1 Month Change
+4.0%
1 Year Change
-58.3%
Year-to-Date Change
-66.4%
From 52W High of $3.07
+113.3%
From 52W Low of $0.48
📊 TOP ANALYST CALLS
Did IVVD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Invivyd is one of their latest high-conviction picks.
Latest IVVD Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, IVVD has a bullish consensus with a median price target of $10.00 (ranging from $10.00 to $10.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $1.03, the median forecast implies a 870.9% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Thomas Shrader at BTIG, projecting a 870.9% upside. Conversely, the most conservative target is provided by Thomas Shrader at BTIG, suggesting a 870.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IVVD Analyst Ratings
3
Buy
0
Hold
0
Sell
IVVD Price Target Range
Low
$10.00
Average
$10.00
High
$10.00
Current: $1.03
Latest IVVD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IVVD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 1, 2026 | BTIG | Thomas Shrader | Buy | Reiterates | $10.00 |
| May 18, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Feb 26, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Dec 23, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Dec 22, 2025 | BTIG | Buy | Initiates | $N/A | |
| Nov 25, 2025 | D. Boral Capital | Hold | Downgrade | $N/A | |
| Nov 3, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Oct 31, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Oct 6, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Oct 6, 2025 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Aug 27, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 25, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Aug 19, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Aug 15, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jun 26, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 26, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| May 28, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 16, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Mar 26, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 20, 2025 | D. Boral Capital | Buy | Maintains | $N/A |
Invivyd Inc. (IVVD) Competitors
The following stocks are similar to Invivyd based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Invivyd Inc. (IVVD) Financial Data
Invivyd Inc. has a market capitalization of $303.45M with a P/E ratio of -3.4x. The company generates $55.87M in trailing twelve-month revenue with a -138.9% profit margin.
Revenue growth is +21.6% quarter-over-quarter, while maintaining an operating margin of -313.9% and return on equity of -60.3%.
Valuation Metrics
Market Cap
$303.45M
Enterprise Value
$127.92M
P/E Ratio
-3.4x
PEG Ratio
0.5x
Price/Sales
5.4x
Growth & Margins
Revenue Growth (YoY)
+21.6%
Gross Margin
+92.5%
Operating Margin
-313.9%
Net Margin
-138.9%
EPS Growth
+21.6%
Financial Health
Cash/Price Ratio
+60.7%
Current Ratio
6.5x
Debt/Equity
4.2x
ROE
-60.3%
ROA
-29.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Invivyd Inc. (IVVD) Business Model
About Invivyd Inc.
What They Do
Develops antibody therapies for viral infections.
Business Model
The company generates revenue by developing and commercializing monoclonal antibody therapies for viral diseases, focusing on high-need areas such as COVID-19 and influenza. Its proprietary technology platform enhances the effectiveness and durability of these therapies, which are offered alongside patient support programs and collaborations with research institutions.
Additional Information
Invivyd Inc. is headquartered in Waltham, Massachusetts, with additional facilities in New Haven, Connecticut. The company emphasizes innovation in antibody engineering and has a strong commitment to advancing public health through partnerships and collaborations in the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
122
CEO
Ms. Heidi Spurling M.S.
Country
United States
IPO Year
2021
Website
www.invivyd.comInvivyd Inc. (IVVD) Latest News & Analysis
Latest News
Quick Summary
Invivyd, Inc. granted options to 17 new non-executive employees for a total of 513,500 shares on June 1, 2026, as part of its 2026 Inducement Plan, complying with Nasdaq rules.
Why It Matters
The granting of stock options to new employees indicates potential growth and confidence in Invivyd's future, which may positively influence stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Invivyd, Inc. has completed enrollment in the Phase 3 DECLARATION trial for VYD2311, a monoclonal antibody aimed at preventing symptomatic COVID-19, with top-line results expected in late Q3 2026.
Why It Matters
Completion of enrollment in a Phase 3 trial for VYD2311 positions Invivyd for potential regulatory approval, impacting its stock value and market perception as results approach.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Invivyd, Inc. (Nasdaq: IVVD) will participate in investor events in June, as announced on May 27, 2026.
Why It Matters
Invivyd's participation in investor events may provide insights into its strategy, performance, and future prospects, potentially influencing stock valuation and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Invivyd Q1 Earnings Call Highlights
23 days ago
Quick Summary
Invivyd (NASDAQ: IVVD) reported progress in its COVID-19 antibody program, year-over-year growth for PEMGARDA, and increased clinical spending for VYD2311 in Q1 2026.
Why It Matters
Invivyd's progress in its COVID-19 antibody program and growth in PEMGARDA may signal strong future revenue, while increased spending on VYD2311 could impact profitability and cash flow.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Invivyd, Inc. (IVVD) held its Q1 2026 earnings call, discussing financial performance and strategic updates. Further details on earnings and projections were provided.
Why It Matters
The Q1 2026 earnings call for Invivyd, Inc. provides insights into the company's financial health, growth prospects, and market performance, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Invivyd reported Q1 2026 net product revenue of $13.7 million, up 22% from Q1 2025. The company has a strong cash position of $184.2 million and anticipates top-line data for VYD2311 in Q3 2026.
Why It Matters
Invivyd's revenue growth and strong cash position indicate financial health, while promising data on VYD2311 may enhance investor confidence in future performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About IVVD Stock
What is Invivyd Inc.'s (IVVD) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Invivyd Inc. (IVVD) has a median price target of $10.00. The highest price target is $10.00 and the lowest is $10.00.
Is IVVD stock a good investment in 2026?
According to current analyst ratings, IVVD has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.03. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IVVD stock?
Wall Street analysts predict IVVD stock could reach $10.00 in the next 12 months. This represents a 870.9% increase from the current price of $1.03. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Invivyd Inc.'s business model?
The company generates revenue by developing and commercializing monoclonal antibody therapies for viral diseases, focusing on high-need areas such as COVID-19 and influenza. Its proprietary technology platform enhances the effectiveness and durability of these therapies, which are offered alongside patient support programs and collaborations with research institutions.
What is the highest forecasted price for IVVD Invivyd Inc.?
The highest price target for IVVD is $10.00 from Thomas Shrader at BTIG, which represents a 870.9% increase from the current price of $1.03.
What is the lowest forecasted price for IVVD Invivyd Inc.?
The lowest price target for IVVD is $10.00 from Thomas Shrader at BTIG, which represents a 870.9% increase from the current price of $1.03.
What is the overall IVVD consensus from analysts for Invivyd Inc.?
The overall analyst consensus for IVVD is bullish. Out of 2 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are IVVD stock price projections?
Stock price projections, including those for Invivyd Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 6:53 AM UTC